SensApp
Super-sensitive detection of Alzheimer’s disease biomarkers in plasma by an innovative droplet split-and stack approach
SensApp aims at developing a super-sensor system that, pushing the sensitivity well below 1 pg/mL, will be able to detect the AD biomarkers (Amyloid-beta, tau, P-tau) in human plasma, thus overcoming the limits of detection usually encountered by standard ELISA protocols. This super-sensor will enable in future a faster and non-invasive early diagnosis of AD simply through a routine blood test, thus opening the route to highly efficient screening programs among the population.
01/01/2019 -> 31/12/2021
More information :http://www.sensapp.eu/